Free Trial
NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

Context Therapeutics logo
$0.82 +0.02 (+3.04%)
Closing price 04:00 PM Eastern
Extended Trading
$0.81 -0.01 (-0.88%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Context Therapeutics Stock (NASDAQ:CNTX)

Key Stats

Today's Range
$0.80
$0.86
50-Day Range
$0.65
$1.21
52-Week Range
$0.64
$2.75
Volume
45,709 shs
Average Volume
387,732 shs
Market Capitalization
$61.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33
Consensus Rating
Buy

Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Remove Ads

Context Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

CNTX MarketRank™: 

Context Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 813th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Context Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Context Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Context Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Context Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Context Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Context Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Context Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.65% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Context Therapeutics has recently increased by 3.78%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Context Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Context Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.65% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Context Therapeutics has recently increased by 3.78%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.04% of the stock of Context Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 14.03% of the stock of Context Therapeutics is held by institutions.

  • Read more about Context Therapeutics' insider trading history.
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

Context Therapeutics (CNTX) Expected to Announce Earnings on Thursday
“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
See More Headlines

CNTX Stock Analysis - Frequently Asked Questions

Context Therapeutics' stock was trading at $1.05 at the beginning of 2025. Since then, CNTX shares have decreased by 19.9% and is now trading at $0.8410.
View the best growth stocks for 2025 here
.

Context Therapeutics Inc. (NASDAQ:CNTX) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.11.

Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

Top institutional investors of Context Therapeutics include MPM Bioimpact LLC (19.61%), Blue Owl Capital Holdings LP (8.48%), Franklin Resources Inc. (5.34%) and Ally Bridge Group NY LLC (2.10%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit.
View institutional ownership trends
.

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
11/06/2024
Today
3/19/2025
Next Earnings (Estimated)
3/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTX
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.33
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+655.8%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.74 per share
Price / Book
1.13

Miscellaneous

Free Float
72,718,000
Market Cap
$62.85 million
Optionable
Not Optionable
Beta
2.06
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CNTX) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners